FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biotechnology and immunology.
EFFECT: bispecific anti-human vascular endothelial growth factor VEGF and human angiopoietin-2 ANG-2 antibodies, methods for producing them, pharmaceutical compositions containing the above antibodies, and using them are described.
13 cl, 26 dwg, 15 tbl, 19 ex
Title | Year | Author | Number |
---|---|---|---|
BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES | 2014 |
|
RU2640253C2 |
BISPECIFIC BIVALENT ANTI-VEGF/ANTI-ANG-2 ANTIBODIES | 2011 |
|
RU2597973C2 |
ANTIBODIES AGAINST HUMAN ANGIOPOIETIN-2 | 2009 |
|
RU2569107C2 |
ANTIBODIES AGAINST HUMAN ANGIOPOIETIN-2 | 2009 |
|
RU2569461C2 |
ANTI-VEGF-ANTIBODY AND ITS PHARMACEUTICAL COMPOSITION FOR PREVENTION, DIAGNOSTICS OR TREATMENT OF CANCER OR ANGIOGENESIS-RELATED DISEASE | 2014 |
|
RU2644245C2 |
HUMANIZED ANTI-VEGF MONOCLONAL ANTIBODY | 2020 |
|
RU2809746C2 |
BISPECIFIC ANTIGEN-BINDING PROTEINS | 2010 |
|
RU2573914C2 |
NOVEL DUAL-TARGETED PROTEINS SPECIFICALLY BINDING TO DLL4 AND VEGF, AND USE THEREOF | 2014 |
|
RU2648154C2 |
CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2015 |
|
RU2812875C1 |
IMPROVED METHODS OF TREATING VASCULARISED MALIGNANT TUMORS | 2015 |
|
RU2692248C2 |
Authors
Dates
2015-02-20—Published
2009-10-07—Filed